

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM513293

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the spelling of the Receiving Party's name in a cover sheet for a Notice of Grant of Security Interest previously recorded on Reel 006209 Frame 0010. Assignor(s) hereby confirms the correct spelling of the Receiving Party's name is ATHYRIUM OPPORTUNITIES III ACQUISITION LP.

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
RECRO PHARMA, INC.		11/17/2017	Corporation: PENNSYLVANIA

RECEIVING PARTY DATA

Name:	Athyrium Opportunities III Acquisition LP
Street Address:	530 Fifth Avenue, Floor 25
Internal Address:	c/o Athyrium Capital Management LP
City:	New York
State/Country:	NEW YORK
Postal Code:	10036
Entity Type:	Limited Partnership: DELAWARE

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Serial Number:	87687125	RECRO
Serial Number:	86457241	INADEX
Registration Number:	4777159	RECRO PHARMA
Serial Number:	86457272	RELIXED
Serial Number:	86861501	REXEVE
Serial Number:	86861522	REXIEVE
Serial Number:	86457244	XEDANX
Serial Number:	86861551	XOLIV

CORRESPONDENCE DATA

Fax Number: 7043782057

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7043312359

Email: iplaw@mvalaw.com, cindigraser@mvalaw.com

Correspondent Name: Moore & Van Allen PLLC

Address Line 1: 100 North Tryon Street

TRADEMARK

Address Line 2: Suite 4700
Address Line 4: Charlotte, NORTH CAROLINA 28202

NAME OF SUBMITTER: James Van Cleave Gambrell

SIGNATURE: /James Van Cleave Gambrell/

DATE SIGNED: 03/07/2019

Total Attachments: 6

source=036251-40-corrective-assign-TM-cover-sheet-3-7-2019#page1.tif

source=036251-40-corrective-assign-TM-cover-sheet-3-7-2019#page2.tif

source=036251-40-corrective-assign-TM-cover-sheet-3-7-2019#page3.tif

source=036251-40-corrective-assign-TM-cover-sheet-3-7-2019#page4.tif

source=036251-40-corrective-assign-TM-cover-sheet-3-7-2019#page5.tif

source=036251-40-corrective-assign-TM-cover-sheet-3-7-2019#page6.tif

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM451438

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
RECRO PHARMA, INC.		11/17/2017	Corporation: PENNSYLVANIA
RECEIVING PARTY DATA			
Name:	ATHYRIUM OPPORTUNITIES III ACQUISITION LP		
Street Address:	530 FIFTH AVENUE, Floor 25		
Internal Address:	C/O ATHYRIUM CAPITAL MANAGEMENT LP		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10036		
Entity Type:	Limited Partnership: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	87687125		
Serial Number:	86457241	INADEX	
Registration Number:	4777159	RECRO PHARMA	
Serial Number:	86457272	RELIXED	
Serial Number:	86861501	REXEVE	
Serial Number:	86861522	REXIEVE	
Serial Number:	86457244	XEDANX	
Serial Number:	86861551	XOLIV	
CORRESPONDENCE DATA			
Fax Number:	7043782057		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	7043312359		
Email:	cindigraser@mvalaw.com, vangambrell@mvalaw.com		
Correspondent Name:	Moore & Van Allen PLLC		
Address Line 1:	3015 Carrington Mill Boulevard, Ste. 400		
Address Line 2:	PO Box 13706		
Address Line 4:	Research Triangle Pa, NORTH CAROLINA 27709		
NAME OF SUBMITTER:	Peter B. Stewart		

OP \$215.00 87687125

SIGNATURE:	/Peter B. Stewart/
DATE SIGNED:	11/17/2017
Total Attachments: 4 source=Executed-trademark-Notices-Recro_Pharma#page1.tif source=Executed-trademark-Notices-Recro_Pharma#page2.tif source=Executed-trademark-Notices-Recro_Pharma#page3.tif source=Executed-trademark-Notices-Recro_Pharma#page4.tif	

NOTICE
OF
GRANT OF SECURITY INTEREST
IN
TRADEMARKS

United States Patent and Trademark Office

Ladies and Gentlemen:


Please be advised that pursuant to the Security Agreement dated as of November 17, 2017 (as the same may be amended, modified, restated or supplemented from time to time, the "Security Agreement") by and among the Grantors party thereto (each a "Grantor" and collectively, the "Grantors") and Athyrium Opportunities III Acquisition LP, as Administrative Agent (the "Administrative Agent") for the Secured Parties referenced therein, the undersigned Grantor has granted a continuing security interest in and continuing lien upon, the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto to the Administrative Agent for the ratable benefit of the Secured Parties.

The undersigned Grantor and the Administrative Agent, on behalf of the Secured Parties, hereby acknowledge and agree that the security interest in the trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto (i) may only be terminated in accordance with the terms of the Security Agreement, (ii) is not to be construed as an assignment of any trademark, trademark license or trademark application.

[Signature pages follow]

Very truly yours,

RECRO PHARMA, INC.
a Pennsylvania corporation

By: 
Name: Ryan Lake
Title: Senior Vice President of Finance
and Chief Accounting Officer

NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS – Recro Pharma, Inc.
RECRO PHARMA, INC.


TRADEMARK
REEL: 006280 FRAME: 0029

Acknowledged and Accepted:

ATHYRIUM OPPORTUNITIES III ACQUISITION LP,
a Delaware limited partnership, as Administrative Agent

By: Athyrium Opportunities Associates III LP, its General Partner

By: Athyrium Opportunities Associates III GP LLC, the General
Partner of Athyrium Opportunities Associates III LP

By: 
Name: Andrew C. Hyman
Title: Authorized Signatory

Schedule 1

**Recro Pharma, Inc.
(Pennsylvania corporation)**

U.S. Trademarks

U.S. Trademarks owned by Recro Pharma, Inc.

<u>Trademark</u>	<u>Registration Number / Application Number</u>	<u>Owner</u>
RECRO	87/687,125	Recro Pharma, Inc.
INADEX	86/457,241	Recro Pharma, Inc.
RECRO PHARMA	4777159 / 86/471,197	Recro Pharma, Inc.
RELIXED	86/457,272	Recro Pharma, Inc.
REXEVE	86/861,501	Recro Pharma, Inc.
REXIEVE	86/861,522	Recro Pharma, Inc.
XEDANX	86/457,244	Recro Pharma, Inc.
XOLIV	86/861,551	Recro Pharma, Inc.